• Product NameABT-263 (Navitoclax)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of 0.5 nM, 1 nM and 1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
• Target NameBcr-Abl inhibitor
• CAS No. 923564-51-6
• Calculated MW 974.61
• Formulation C47H55ClF3N5O6S3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
  Pathways:Angiogenesis; Cytoskeletal Signaling
  Receptor:Bcl-2; Bcl-w; Bcl-xL
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL (102.6 mM)
  Appearance:Off-white Color Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Tse C, et al. Y Res. 2008, 68(9), 3421-3428.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting